HANGZHOU and SHAOXING, China, Sept. 4, 2023 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) is set to make waves as it steps onto the global healthcare stage. Exciting news unfolds as Ascletis announces its eagerly anticipated participation in the prestigious Morgan Stanley 21st Annual Global Healthcare Conference.
Mark your calendars for an electrifying fireside chat featuring John Gargiulo, the Chief Business Officer of Ascletis, scheduled for 2:15 pm EST on Wednesday, September 13, 2023 (that’s 2:15 am Beijing time on Thursday, September 14, 2023). This engaging conversation promises to pack 30 minutes full of insights and revelations.
The Morgan Stanley 21st Annual Global Healthcare Conference, running from Monday, September 11, to Wednesday, September 13, 2023, in New York, U.S., is poised to be a pivotal event on the healthcare calendar. With a lineup of over 200 prominent companies, it’s the ultimate platform where top-tier executives, investors, and analysts converge to spark innovation and forge collaboration. Each fireside chat kicks off with a riveting Q&A session between C-level leaders and a Morgan Stanley moderator, followed by an interactive dialogue with the eager audience.
Meet Ascletis, the trailblazing biotech firm that’s taking the world by storm, listed on the vibrant Hong Kong Stock Exchange under the symbol 1672.HK. With a mission that spans the entire spectrum of discovery, development, manufacturing, and commercialization, Ascletis is a powerhouse of innovation.
What sets Ascletis apart? It starts with a remarkable leadership team, armed with an arsenal of expertise and an enviable track record. Their collective vision is clear: to address critical unmet medical needs on a global scale, focusing on three pivotal therapeutic areas—viral diseases, the ever-elusive non-alcoholic steatohepatitis (NASH), and the complex landscape of oncology.
Ascletis is not just dreaming; they’re executing with unparalleled precision. Their dynamic drug pipeline is a testament to their unwavering commitment to lead the charge in global competition. With multiple drug candidates in the R&D pipeline, Ascletis is making waves.
At the forefront are their most advanced champions: ASC22, poised to revolutionize the landscape of CHB functional cure; ASC40, dedicated to conquering acne; ASC40, fearlessly battling recurrent glioblastoma; ASC40, pioneering solutions for NASH; ASC41, rewriting the narrative on NASH; and ASC61, igniting hope in the realm of advanced solid tumors.
In the world of biotech, Ascletis is not just a player; it’s a visionary force to be reckoned with—a symbol of innovation, determination, and a relentless pursuit of a healthier world.